Search

Motexafin lutetium

Motexafin lutetium (MLu) is a second-generation photosensitizer for photodynamic therapy (PDT) of cancer. It belongs to the family of drugs called metallotexaphyrins. Also called lutetium texaphyrin.

Matrix-M

[L27981] This compound is administered alongside vaccines to enhance biological functions: creating robust and long-lasting immune responses that may allow for dose-sparing of vaccines.

Daglutril

Daglutril is an orally active, mixed neutral endopeptidase/endothelin converting enzyme inhibitor under development for the treatment of essential hypertension and congestive heart failure.

Sulfaisodimidine

Sulfaisodimidine also called sulfisomidine is an antibacterial product that has been studied for the treatment of urinary tract infections in the 1950s, however, it is unclear whether this drug has been … officially approved for use anywhere [A175672].

Rilonacept

Rilonacept functions as an interleukin 1 inhibitor and is used in the treatment of CAPS, also known as cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome (FCAS)

Itruvone

Itruvone is under investigation in clinical trial NCT02322086 (A Phase 2 Study of Cellular and Immunologic Changes in the Skin of Subjects Receiving PH-10).

Remikiren

Remikiren is an orally active, high specificity renin inhibitor.

Nitrofurantoin

[A179824] This drug is more resistant to the development of bacterial resistance because it acts on many targets at once.

Epratuzumab

This agent may subsequently be well matched for use in oncology and the treatment of inflammatory autoimmune disorders, such as lupus.

Cyd dengue virus serotype 3 live (attenuated) antigen